RedHill Biopharma develops medicines for gastrointestinal and infectious diseases, promoting drugs like Talicia for H. pylori infections and Aemcolo for travelers’ diarrhea. Their late-stage programs include RHB-204, opaganib, RHB-107, RHB-104, and RHB-102.
RDHL has been in the news recently: NImmune Biopharma's CEO, Josep Bassaganya-Riera, will discuss the Phase 3 drug omilancor at the UBS Virtual Biotechnology Symposium on September 18-19, 2024. WestGene Biopharma presented encouraging clinical results for its mRNA vaccine WGc-043, which targets EBV-positive tumors, at ESMO 2024, highlighting its safety and efficacy in treating advanced cancers.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
